Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
CONy 2023
ACTRIMS 2023
ISC 2023
EHC 2022
AES 2022
WSC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
James F. Howard Jr.
3:24
Optimization of myasthenia gravis management: knowledge gaps
James F. Howard Jr.
• 12 Apr 2022
2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr.
• 12 Apr 2022
7:04
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+
James F. Howard Jr.
• 12 Apr 2022
2:05
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis
James F. Howard Jr.
• 12 Apr 2022
2:11
The expanding treatment landscape for myasthenia gravis
James F. Howard Jr.
• 7 Apr 2021
1:34
REGAIN study and extension trial of eculizumab in myasthenia gravis
James F. Howard Jr.
• 7 Apr 2021
1:02
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study
James F. Howard Jr.
• 7 Apr 2021
0:45
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders
James F. Howard Jr.
• 7 Apr 2021
4:59
ADAPT analysis: efgartigimod for generalized myasthenia gravis
James F. Howard Jr.
• 7 Apr 2021
